🇺🇸 FDA
Patent

US 10434174

Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells

granted A61KA61K2039/505A61K31/282

Quick answer

US patent 10434174 (Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
37
CPC classes
A61K, A61K2039/505, A61K31/282, A61K31/555, A61K33/243